Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal

Esperion CEO Tim Mayleben has fattened the biotech’s cash reserves with an extra $200 million as he lays the foundation for the projected commercial launch of bempedoic acid next year.